1-7 of 7
Marilyn J. Telen
Close
Sort by
Journal Articles

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Clinical Trials & Observations
Santosh L Saraf, Robert Ward Hagar, Modupe Idowu, Ifeyinwa Osunkwo, Kimberly Cruz, Frans A Kuypers, R. Clark Brown, James Geib, Maria D Ribadeneira, Patricia Schroeder, Eric Wu, Sanjeev Forsyth, Patrick F. Kelly, Theodosia A. Kalfa, Marilyn J. Telen
Journal: Blood Advances
Blood Adv bloodadvances.2023012467.
https://doi.org/10.1182/bloodadvances.2023012467
Published: 2024
Includes: Supplemental data
Journal Articles

Preferences for potential benefits and risks for gene therapy in the treatment of sickle cell disease

Juan Marcos Gonzalez Sepulveda, Jui-Chen Yang, Shelby D. Reed, Ting-Hsuan Lee, Xinyi Ng, Sarah Stothers, Telba Irony, Martin Ho, Jennifer A. Rothman, Sherif Badawy, Carolyn Rowley, Jane Little, Nirmish R. Shah, Kaiwen Li, Marilyn J. Telen
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7371–7381.
https://doi.org/10.1182/bloodadvances.2023009680
Published: 2023
Includes: Supplemental data
Journal Articles

Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy

Melanie E. Garrett, Karen L. Soldano, Kyle N. Erwin, Yingze Zhang, Victor R. Gordeuk, Mark T. Gladwin, Marilyn J. Telen, Allison E. Ashley-Koch
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4782–4793.
https://doi.org/10.1182/bloodadvances.2022007451
Published: 2023
Includes: Supplemental data
Journal Articles

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis

Clinical Trials & Observations
Kenneth I. Ataga, Qingning Zhou, Santosh L. Saraf, Jane S. Hankins, Emily J. Ciccone, Laura R. Loehr, Allison E. Ashley-Koch, Melanie E. Garrett, Jianwen Cai, Marilyn J. Telen, Vimal K. Derebail
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4461–4470.
https://doi.org/10.1182/bloodadvances.2022007693
Published: 2022
Includes: Supplemental data
Journal Articles

Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Clinical Trials & Observations
Marilyn J. Telen
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3457–3465.
https://doi.org/10.1182/bloodadvances.2020001469
Published: 2020
Journal Articles

Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo

Timothy J. McMahon, Siqing Shan, Daniel A. Riccio, Milena Batchvarova, Hongmei Zhu, Marilyn J. Telen, Rahima Zennadi
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2586–2597.
https://doi.org/10.1182/bloodadvances.2019031633
Published: 2019
Includes: Multimedia, Supplemental data
Journal Articles

Depression, quality of life, and medical resource utilization in sickle cell disease

Clinical Trials & Observations
Soheir S. Adam, Charlene M. Flahiff, Shital Kamble, Marilyn J. Telen, Shelby D. Reed, Laura M. De Castro
Journal: Blood Advances
Blood Adv (2017) 1 (23): 1983–1992.
https://doi.org/10.1182/bloodadvances.2017006940
Published: 2017
Includes: Supplemental data